Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 401–500 of 1,001
Jiang, Y. J., Yusoff, N. M., Du, J., Moses, E. J., & Lin, J. (2024) · World Journal of Stem Cells · doi:10.4252/wjsc.v16.i7.760 · Cited by 17
Yeh, M., Huang, J., Dai, C., Huang, C., Yu, M., & Chuang, W. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2388790 · Cited by 16
“There is a dose-dependent association between the risk of mortality and the stage of fibrosis [22,23].”
Kubotsu, Y., Sakamoto, Y., Tago, M., Chihara, A., Norita, M., Inadomi, C., Inoue, K., Takayanagi, H., Tanaka, K., Isoda, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64809 · Cited by 19
Baek, J. W., Yang, Y. S., Jung, K. J., Kimm, H., Kim, S. Y., Lee, S., & Jee, S. H. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.09.001 · Cited by 20
Dabbah, S., Mishani, I., Davidov, Y., & Ben‐Ari, Z. (2024) · Digestion · doi:10.1159/000542241 · Cited by 19
Lazure, P., Tomlinson, J., Kowdley, K. V., Magni, P., Santos, R. D., Jacobs, G., & Murray, S. (2022) · Liver International · doi:10.1111/liv.15324 · Cited by 18
Self-citationSebastiani, G., Milić, J., Kablawi, D., Gioè, C., Hinai, A. S. A., Lebouché, B., Tsochatzis, E. A., Finkel, J., Ballesteros, L. R., Ramanakumar, A. V., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad203 · Cited by 16
“C A recent study of 1773 NAFLD patients showed that liver fibrosis stage was not associated with incident cardiac events and nonhepatic cancers(46).”
BackgroundAssociation between advanced fibrosis and epigenetic age acceleration among individuals with MASLD
Wang, H., Liu, Z., Fan, H. X., Guo, C., Zhang, X., Li, Y., Zhao, S., Dai, L., Zhao, M., & Zhang, T. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02181-0 · Cited by 18
“Advanced fibrosis was associated with increased risks of liver-related complications and all-cause mortality among individuals with MASLD [2, 3].”
Stroes, A.-S. R., Draijer, L. G., Chegary, M., Kreier, F., van Os, E., Goede, J., Boonstra, V., Westerbeek, I., de Jongh, S., Kusters, M., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.05.011 · Cited by 15
Kosick, H. M.-K., McIntosh, C., Bera, C., Fakhriyehasl, M., Shengir, M., Adeyi, O. A., Amiri, L., Sebastiani, G., Jhaveri, K. S., & Patel, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-09288-1 · Cited by 19
“Prior studies of serum-based NIT, including NFS, FIB-4, and APRI have shown mixed results in prediction of both liver-related outcomes and mortality 5,13,41–54 .”
Ajmera, V. H., Vuppalanchi, R., Khalili, M., Sheikh, M. Y., Risser, J. A., Klein, S., Tincopa, M. A., Madamba, E. V., Singh, S., Siddiqi, H., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70516 · Cited by 17
“The risk of liver-related morbidity and mortality rises exponentially with the development of progressive stages of fibrosis, assessed by liver biopsy or liver stiffness measurement [5–7].”
Self-citationThe many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
Self-citationPark, A., Choi, S. J., Park, S., Kim, S. M., Lee, H., Joo, M., Kim, K. K., Kim, D., Chung, D. H., Im, J.-B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095035 · Cited by 16
Fujiwara, N., & Nakagawa, H. (2023) · Cancer Science · doi:10.1111/cas.15925 · Cited by 17
“…et al. revealed that CXCR6 + CD8 T cells, which originated from CD122-expressing T cells through downregulation of transcriptional factor FOXO1 by interleukin-15, obtained the MHC- class- I-independent killing capability against hepatocytes, termed as “auto-aggression,” by being exposed to…”
BackgroundHuang, J., Chang, T., Yeh, M., Shen, F., Tai, C., Chen, J., Huang, Y., Hsu, C., Cheng, P., Lin, C., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000571 · Cited by 17
“[11,12] In addition, diabetes promotes the development of HCC.”
BackgroundA Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis
Shah, N., & Sanyal, A. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003215 · Cited by 17
Self-citationNjei, B. M., Mezzacappa, C., John, B. V., Serper, M., Kaplan, D. E., Taddei, T. H., & Mahmud, N. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08764-4 · Cited by 18
“5 Cause-Specific Hazard Analysis for Liver-Related, CV-Related, and Non-Liver/Non-CV-Related Mortality Smoking has been associated with an increase in insulin resistance, which is the pathophysiological hallmark of metabolic syndrome [13, 27].”
Eriksen, P. L., Thomsen, K. L., Sørensen, M., Vilstrup, H., & Hvas, A. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.02.023 · Cited by 15
Potential Therapeutic Targets and Promising Agents for Combating NAFLD
Umemura, A., Kataoka, S., Okuda, K., Seko, Y., Yamaguchi, K., Moriguchi, M., Okanoue, T., & Itoh, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10040901 · Cited by 15
Sinakos, E., Liava, C., & Loomba, R. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0704 · Cited by 19
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
Evolving challenges with long‐term care of liver transplant recipients
Odenwald, M. A., Roth, H. F., Reticker, A., Segovia, M. C., & Pillai, A. A. (2023) · Clinical Transplantation · doi:10.1111/ctr.15085 · Cited by 16
“62 However, a recent study found that patients transplanted for MASH at ≥ 65 years-old or those with diabetes have worse survival than their counterparts, 65 and similar to the non-LT population, 66 cardio-vascular events were common causes of mortality.”
BackgroundNASH cirrhosis trials and major adverse liver outcomes: Big data needed
Noureddin, M., & Harrison, S. A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.022 · Cited by 17
Oh, J. H., & Jun, D. W. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0140 · Cited by 15
A turning point in hepatology? EASL reflects on the first approved drug for MASH
Francque, S., Krag, A. A., Shawcross, D. L., & Zelber‐Sagi, S. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.036 · Cited by 16
Detecting at-risk steatotic liver disease and liver fibrosis in the community
Adams, L. A., Thiele, M. S., & Tsochatzis, E. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001400 · Cited by 15
Kim, Y., Rydqvist, P., Ramezani, T., Haas, J. S., Bantel, H., Buggisch, P., Geier, A., Hofmann, W. P., Mauss, S., Roeb, E., et al. (2025) · Liver International · doi:10.1111/liv.70225 · Cited by 14
“Liver fibrosis serves as a key prognostic marker for MASH, increasing the risk of mortality as patients with advanced fibrotic stages are more susceptible to complications such as HCC [15].”
Wong, E. S. P., Chen, Y., Kong, G., Chia, J., Zhang, A. A. Y., Mehta, A., Jayabaskaran, J., Chong, B., Cao, G., Nah, B. K. Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-12583-6 · Cited by 17
Ratziu, V., Surabattula, R., Bugianesi, E., Schattenberg, J. M., Myneni, S. R., Rosso, C., Armandi, A., Pais, R., Kara, L., Charlotte, F., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-335598 · Cited by 15
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
Lazarus, J. V., Agirre‐Garrido, L., Díaz, L. A., Danpanichkul, P., Kivuyo, S. L., Kondili, L. A., Hagström, H., Takahashi, H., Pericàs, J. M., Spearman, C. W., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.42750 · Cited by 18
Optimal Indicator of Death for Using Real-World Cancer Patients' Data From the Healthcare System
Jang, S., Kwon, S., Min, S., Jo, A.-R., Lee, E., & Nam, J. H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906211 · Cited by 14
“For this reason, survival-associated outcomes are presented as the major outcomes in most clinical studies, including clinical trials and epidemiological studies; they are also key parameters in studies of health policy, health economics, and outcomes research (Podrid and Myerburg, 2005; Khera et al., 2021; Sanyal et…”
BackgroundFox, R. K., Chu, J. N., Goldman, M. L., Islam, K. B., & Brandman, D. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000024 · Cited by 15
Villarroel, C., Karim, G., Sehmbhi, M., Debroff, J., Weisberg, I. S., & Dinani, A. M. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.008 · Cited by 15
“3 Liver fi brosis as a result of MASLD is associated with major adverse liver outcomes and all-cause mortality, 4,5 with atherosclerotic cardiovascular disease being the principal cause of death in patients with MASLD.”
BackgroundKoch, V., Gotta, J., Chernyak, V., Cengiz, D. S., Torgashov, K., Eichler, K., Vilgrain, V., Martin, S. S., Ziegengeist, N. S., Konrad, P., et al. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29560 · Cited by 14
Lan, T., & Tacke, F. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156015 · Cited by 17
A genetic hypothesis for burnt‐out steatohepatitis
Valenti, L. V. C., Romeo, S., & Pajvani, U. B. (2021) · Liver International · doi:10.1111/liv.15103 · Cited by 15
Song, Q., Liu, S., Bi, Y., Chen, S., Wu, S., & Cai, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.889597 · Cited by 15
“In addition, participants with progressive liver fibrosis experienced more serious insulin resistance (36), and those with cirrhosis also had a higher incidence of T2DM than those with mild or moderate fibrosis (37).”
BackgroundPre-emptive TIPSS in Acute Variceal Bleeding: Current Status, Controversies, and Future Directions
Wong, Y. J., Ho, W. L. D., & Abraldeṣ, J. G. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00240 · Cited by 18
Seo, I., Lee, H. S., & Lee, Y. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01642-1 · Cited by 15
“In the recent prospective study, patients with a higher histological stage of NAFLD have a higher incidence of T2DM and a higher risk of all-cause mortality [15].”
BackgroundExosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
Qi, X., & Lai, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113501 · Cited by 17
“A recent clinical prospective study led by NASH Clinical Research Network (CRN) showed that NASH-caused advanced fibrosis stages (F3 and F4) were associated with increased risks of liver-related complications, including hepatocellular carcinoma and death [11].”
BackgroundKanemitsu‐Okada, K., Abe, M., Nakamura, Y., Miyake, T., Watanabe, T., Yoshida, O., Koizumi, Y., Hirooka, M., Tokumoto, Y., Matsuura, B., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032509 · Cited by 15
Alonso‐Peña, M., Barrio, M. D., Peleteiro‐Vigil, A., Jiménez-González, C., Santos‐Laso, Á., Arias, M., Iruzubieta, P., & Crespo, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310718 · Cited by 19
“It has been shown that the incidence of liver-related complications and all-cause mortality increased with the degree of fibrosis, with fibrosis grades F3 and F4 being associated with an increased risk of liver complications and all-cause mortality [4].”
BackgroundMethodInfluentialDunn, N., Verma, N., & Dunn, W. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103184 · Cited by 16
Ali, A.-R., Samir, A. E., & Guo, P. (2023) · IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW) · doi:10.1109/cvprw59228.2023.00310 · Cited by 13
“The stage of liver fibrosis at the time of diagnosis has been shown to be the best indicator of negative outcomes for patients with excess liver fat [8].”
BackgroundHarrison, S. A., Dubourg, J., Knott, M., & Colca, J. R. (2023) · Hepatology · doi:10.1097/hep.0000000000000710 · Cited by 14
Siddiqui, M. S., Muthiah, M. D., Satapathy, S. K., Patidar, K. R., Bhat, M., Brandman, D., Watt, K. D. S., & Rinella, M. E. (2023) · Hepatology · doi:10.1097/hep.0000000000000720 · Cited by 14
Yardeni, D., Shiloh, A., Lipnizkiy, I., Nevo-Shor, A., Abu‐Freha, N., Munteanu, D., Novack, V., & Etzion, O. (2023) · Scientific Reports · doi:10.1038/s41598-023-48819-6 · Cited by 14
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
Samanta, A., & Sarma, M. S. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i4.511 · Cited by 14
Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
Danielsson, O., Vesterinen, T., Arola, J. T., Åberg, F. O., & Nissinen, M. J. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002785 · Cited by 14
Kendall, T. J., Chng, E., Ren, Y., Tai, D., Ho, G., & Fallowfield, J. A. (2024) · Liver International · doi:10.1111/liv.16062 · Cited by 17
“3 Critically, not all people with MASLD develop adverse liver-related events or die, 4 but there is a lack of prognostic biomarkers to allow the implementation of personalised approaches to disease management.”
Allen, A. M., Arab, J. P., & Wong, V. W. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00990-5 · Cited by 16
“…scores (for example NAFLD fibrosis score (NFS) and fibrosis-4 index (FIB4)) and imaging (such as transient elastography and MRI-based modalities) have become essential in diagnosing, staging and monitoring MASLD, thereby reducing the need and reliance on invasive techniques such as liver biopsy 8 .”
Pirola, C. J., Gianotti, T. F., & Sookoian, S. C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18468 · Cited by 14
MASLD as a non-communicable disease
Sookoian, S. C., Pirola, C. J., & Sanyal, A. J. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01039-x · Cited by 14
Self-citationOrgan damage proteomic signature identifies patients with MASLD at risk of systemic complications
Pirola, C. J., Diambra, L. A., Gianotti, T. F., Castaño, G. O., Martino, J. S., Garaycoechea, M. E., & Sookoian, S. C. (2025) · Hepatology · doi:10.1097/hep.0000000000001346 · Cited by 15
Pelusi, S., Bianco, C., Colombo, M., Cologni, G., Poggio, P. D., Pugliese, N., Prati, D., Pigozzi, M. G., D’Ambrosio, R., Lampertico, P., et al. (2023) · Liver International · doi:10.1111/liv.15577 · Cited by 15
Țâru, M.-G., & Lupșor‐Platon, M. (2023) · Cancers · doi:10.3390/cancers15164097 · Cited by 15
“F4) [23], and also provided very similar prognostic information relied on literature-based cutoffs [142].”
BackgroundNonalcoholic Fatty Liver Disease. Reply.
Sanyal, A. J., Natta, M. L. V., & Tonascia, J. (2022) · PubMed · doi:10.1056/nejmc2118255 · Cited by 4
Self-citationMeaning of non‐overlapping patients between the MAFLD and NAFLD definitions
Chan, W., & Wong, V. W. (2022) · Liver International · doi:10.1111/liv.15142 · Cited by 16
Allen, A. M., Lazarus, J. V., Alkhouri, N., Noureddin, M., Wong, V. W., Tsochatzis, E. A., de Avila, L., Racila, A., Nader, F., Mark, H. E., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000678 · Cited by 16
Ünalp–Arida, A., & Ruhl, C. E. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07707-1 · Cited by 12
Friedman, S. L., & Sanyal, A. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000389 · Cited by 14
Self-citationIdentification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics
Younossi, Z. M., Henry, L. L., Isaacs, S. D., & Cusi, K. J. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.06.012 · Cited by 15
Koelsch, N. J., Mirshahi, F., Aqbi, H. F., Saneshaw, M., Idowu, M. O., Olex, A. L., Sanyal, A. J., & Manjili, M. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-39020-w · Cited by 12
“A shift in immunological pattern from a dominant adaptive immunity to innate immunity alters the immune cells function and creates a collective function beyond its cellular constituents: DESeq2 was utilized to assess differences in the entire immune cell population (1) compared to each immune cell type components, inc…”
MethodSelf-citationNomoto, H., Takahashi, Y., Takano, Y., Yokoyama, H., Tsuchida, K., Nagai, S., Miya, A., Kameda, H., Cho, K. Y., Nakamura, A., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082163 · Cited by 15
“The all-cause mortality and incidence of liver-related complications increase with worsening liver fibrosis in subjects with NAFLD, and subjects with progressive fibrosis have a higher incidence of T2DM [4].”
BackgroundLin, R., Zhou, J., Sun, Q., Xin, X., Hu, Y., Zheng, M., & Feng, Q. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17889 · Cited by 13
“Given that liver fibrosis severity based on NAFLD histology strongly correlates with liver-related morbidity and mortality, 4,36–39 reversing fibrosis is crucial in NASH treatment.”
Samala, N. R., Xin, Y., Wilson, L., Yates, K. P., Loomba, R. S., Hoofnagle, J. H., & Chalasani, N. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002756 · Cited by 13
Self-citationLoomba, R. S., Clark, G., Teckman, J. H., Ajmera, V. H., Behling, C. A., Brantly, M., Brenner, D. A., D'Armiento, J. M., Fried, M. W., Iyer, J. S., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17967 · Cited by 13
“27 While this may imply that only those with moderate- to-severe fibrosis represent the population of concern, as in other liver diseases, a residual risk for de novo hepatocellular carcinoma may exist even at lower fibrosis stages or in treated disease (i.e. having achieved removal of a primary…”
BackgroundSelf-citationTincopa, M. A., & Loomba, R. S. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1788277 · Cited by 15
Self-citationLin, K.-H., Gómez, E. V., Corey, K. E., Connelly, M. A., Gupta, S. K., Lake, J. E., Chalasani, N., & Gawrieh, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02317-4 · Cited by 12
“Indeed, CVD is a leading cause of death in patients with MASLD [42, 43].”
BackgroundSelf-citationRole of Complement in Liver Diseases
Prado, L. G., & Nagy, L. E. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1795143 · Cited by 13
MOTS-c mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3
Chen, F., Li, Z., Wang, T., Fu, Y., Lyu, L., Xing, C., Li, S., & Li (2025) · Scientific Reports · doi:10.1038/s41598-025-03526-2 · Cited by 16
“Notably, the risk of death in T2DM patients is greatly increased after liver fibrosis enters the advanced stage 30 .”
Shi, Y., Kim, S. U., Yip, T. C., Tsochatzis, E. A., Petta, S., Nakajima, A., Hagström, H., Bugianesi, E., Chan, W., Boursier, J., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.001 · Cited by 16
Self-citationBril, F., Bolla, P., Huynh, K., & Bobba, S. S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf110 · Cited by 14
“…their increased risk of developing hepatocellular carcinoma, requiring a liver transplant, liver-related mortality, and cardiovascular mortality [3], these findings should underscore the importance of implementing successful screening strategies, as well as early initiation of effective…”
InfluentialEvaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
Abeysekera, K. W. M., Orr, J. G., Gordon, F. H., Howe, L. D., Hamilton-Shield, J. P., Heron, J., & Hickman, M. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02401-y · Cited by 12
“Unlike NAFL, it is fibrosis that is associated with liver related mortality [5].”
BackgroundYi, M., Peng, W. J., Teng, F., Kong, Q., & Chen, Z. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002462 · Cited by 20
Santos, M. L., Corma‐Gómez, A., Fernández‐Fuertes, M., González‐Serna, A., Rincón, P., Real, L. M., Pineda, J. A., & Macías, J. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.11.004 · Cited by 12
Cordero, A., Escribano, D., Quintanilla, M. A., López-Ayala, J. M., Masiá, M. D., Morallón, D. C., Rey-Rañal, E. M., Arribas, J. M., & Zuazola, P. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2022.12.013 · Cited by 12
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 13
Boustany, A., Onwuzo, S., Zeid, H. K. A., Almomani, A., Kumar, P. N., Hitawala, A. A., & Asaad, I. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16163 · Cited by 12
Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link
Effenberger, M., Grander, C., Grabherr, F., & Tilg, H. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00069 · Cited by 17
“5,6 Thus far, no medical therapies have been approved for the treatment of NAFLD.”
BackgroundFatty Liver Disease: Enter the Metabolic Era
Wegermann, K., Moylan, C. A., & Naggie, S. (2023) · Current HIV/AIDS Reports · doi:10.1007/s11904-023-00669-7 · Cited by 12
“MASH can result in liver fibrosis, which is scored histopathologically from F0 (no fibrosis) to F4 (cirrhosis) and strongly associates with liver-related outcomes [3].”
Krag, A. A., & Rinella, M. E. (2024) · Nature Medicine · doi:10.1038/s41591-024-02849-3 · Cited by 13
Pons, M., Rivera‐Esteban, J., Manzano-Núñez, R., Bañares, J., Bermúdez, M., Vargas, V., Salcedo, M. T., Castells, L., Augustín, S., Mínguez, B., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092466 · Cited by 14
“5/100 patients-year for F0–2, around 2/100 patients-year for F4, and close to 4/100 patients-year for F3 [8], the latter of which is similar to the overall cumulative incidence in our cohort.”
BackgroundResultInfluentialNoninvasive Algorithms for the Case Finding of “At-Risk” Patients with NAFLD
Castéra, L., & Boursier, J. (2022) · Seminars in Liver Disease · doi:10.1055/s-0042-1751081 · Cited by 12
Han, X., Zhang, X., Liu, Z., Fan, H., Guo, C., Wang, H., Gu, Y., & Zhang, T. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13564 · Cited by 11
James, M., Smuk, M., Rahman, N., Black, G. B., & Alazawi, W. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70080 · Cited by 13
“…cirrhosis, decompensation, and the development of hepatocellular carcinoma (HCC), all of which have a substantial impact on health-related quality of life [4], morbidity, and mortality [5], with the greatest socioeconomic burden of MASLD associated with the late stages of the disease [6].”
The pivotal role of cytokines in liver disease pathogenesis and therapeutic potential
Li, L., Li, X., & Zhang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1694582 · Cited by 15
“Several cellular components or molecular pathways of NASH be targeted simultaneously to achieve anticipative therapeutic goals (167 – 171).”
Aguado, D. M., Arnouk, J., Liang, J., Lara‐Romero, C., Behari, J., Furlan, A., Jiménez-Pastor, A., Ten‐Esteve, A., Alfaro‐Cervelló, C., Bauza, M. E., et al. (2023) · Liver International · doi:10.1111/liv.15766 · Cited by 13
“26 Therefore, identifying significant fibrosis can carry the identification of MASH histological endpoint, specifically in high-prevalence settings.”
BackgroundTian, M., Hou, J., Liu, Z., Li, Z., Huang, D., Zhang, Y., & Ma, Y. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106517 · Cited by 11
Sultanik, P., Kheloufi, L., Leproux, A., Bouzbib, C., Mouri, S., Santiago, A., Galanaud, D., Navarro, V., Sakka, M., Rudler, M., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18148 · Cited by 14
“This is in line with new data 33 showing that OHE can be the first cause of cirrhosis decompensa - tion, especially in patients with metabolic syndrome accounting for more than half of our patients.”
Naoumov, N. V., Kleiner, D. E., Chng, E., Brees, D., Saravanan, C., Ren, Y., Tai, D., & Sanyal, A. J. (2024) · Liver International · doi:10.1111/liv.16092 · Cited by 12
“9 Furthermore, up to 22% of patients with bridging fibrosis were shown to progress to MASH cirrhosis over a median follow-up of 2 years.”
Self-citationVaz, K., Kemp, W. W., Majeed, A., Lubel, J. S., Magliano, D. J., Glenister, K., Bourke, L., Simmons, D. S., & Roberts, S. K. (2024) · Hepatology International · doi:10.1007/s12072-024-10748-5 · Cited by 11
“Only a fraction of people with NAFLD develop cirrhosis, which is the principal factor in predicting liver-related morbidity and mortality [3].”
Malandris, K., Katsoula, A., Liakos, A., Karagiannis, T., Sinakos, E., Γιουλεμέ, Ό., Klonizakis, P., Theocharidou, E., Gigi, E., Bekiari, E., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16142 · Cited by 19
Huang, L., Wang, M.-Y., Xin, F., Yang, R., Zeng, J., Ren, T., & Fan, J. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.04.006 · Cited by 13
Non-invasive assessment of liver fibrosis in MASLD: the need of sex-adjusted scores
Novielli, F., Matteis, C. D., Moschetta, A., & Crudele, L. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2557243 · Cited by 15
“Research conducted by Sanyal et al. (2021) [46] found that individuals with NFS levels exceeding 0.675 had a 3.2 times greater likelihood of developing CAD and 2.8 times higher risk of experiencing major adverse cardiovascular events (MACE), including myocardial infarction and stroke, with…”
InfluentialA non-apoptotic caspase-8–meteorin pathway in hepatocytes promotes MASH fibrosis
Wang, X., Moore, M. P., Shi, H., Xiao, Y., Zhang, J., Faccioli, L. A. P., Hu, Z., Khalid, S., Saleheen, D., Stupack, D. G., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01355-1 · Cited by 17
“…therapeutic implications, based on two key points: first, liver fibrosis is a major contributor to both liver-and non-liver-related mortality in MASH, with limited therapeutic options 4,5 ; second, therapeutic siRNAs that silence pathogenic genes exclusively in hepatocytes are in clinical use 26 .”
Schmid, A., Arians, M., Karrasch, T., Pons‐Kühnemann, J., Schäffler, A., Roderfeld, M., & Roeb, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071756 · Cited by 13
Wang, X., Li, Y., Li, Y., Liu, P., Liu, S., & Pan, Y. (2022) · Stem Cells International · doi:10.1155/2022/3242482 · Cited by 14
“The lack of therapeutic options and hepatic complications underlie the limited treatment of advanced HCC [5, 6].”
BackgroundHepatocellular Carcinoma Chemoprevention with Generic Agents
Rasha, F. A., Paul, S., Simon, T. G., & Hoshida, Y. (2022) · Seminars in Liver Disease · doi:10.1055/a-1942-6693 · Cited by 12
Alomari, M., Rashid, M. U., Chadalavada, P. N., Ragheb, J. G., Zafar, H., Suarez, Z. K., Khazaaleh, S., Gonzalez, A. J., & Castro, F. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i4.477 · Cited by 13
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.